恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》

新浪科技2025-12-15

新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》（《CA： A Cancer Journal for Clinicians》）（影响因子高达232.4），这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。　　据介绍，FZOCUS-1研究是一项在全国54家中心开展、历时六年的随机双盲安慰剂对照Ⅲ期临床试验，共纳入674例患者，旨在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2591970396?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-15 13:59","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2591970396","market":"hk","top_or_hot":-1,"title":"恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》","media":"新浪科技","content":"<div>\n<p>新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》（《CA： A Cancer Journal for Clinicians》）（影响因子高达232.4），这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。\n　　据介绍，FZOCUS-1研究是一项在全国54家中心开展、历时六年的随机双盲安慰剂对照Ⅲ期临床试验，共纳入674例患者，旨在...</p>\n\n<a href=\"https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-15 13:59 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml><strong>新浪科技</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》（《CA： A Cancer Journal for Clinicians》）（影响因子高达232.4），这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。\n　　据介绍，FZOCUS-1研究是一项在全国54家中心开展、历时六年的随机双盲安慰剂对照Ⅲ期临床试验，共纳入674例患者，旨在...</p>\n\n<a href=\"https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2495084118.USD","symbol_name":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml","article_id":"2591970396","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591970396","pubTimestamp":1765778340,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》 ，这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。在HRD阳性人群，FZOCUS-1研究证实PARP抑制剂单药运用即可实现理想疗效，避免联合用药带来的副作用与经济负担。　　“FZOCUS-1研究全文在《CA》的成功发表，是中国临床肿瘤学研究的重要里程碑。”","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0239":"医药制造","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","CA":"Xtrackers California Municipal Bond ETF","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0183":"MSCI概念","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0188":"融资融券","BK0012":"证金概念","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","01276":"恒瑞医药","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0028":"国家队","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK1191":"制药","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK0060":"抗癌","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0196":"行业龙头"},"translate_title":"Hengrui Medicine's ovarian cancer treatment drug fluzoparib FZOCUS-1 study was included in the top global oncology journal \"CA\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"CA":1.5,"01276":1.5},"content_text":"新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》（《CA： A Cancer Journal for Clinicians》）（影响因子高达232.4），这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。\n　　据介绍，FZOCUS-1研究是一项在全国54家中心开展、历时六年的随机双盲安慰剂对照Ⅲ期临床试验，共纳入674例患者，旨在评估恒瑞医药自主研发的全国首个PARP抑制剂氟唑帕利（单药或联合抗血管生成药物阿帕替尼）用于晚期卵巢癌一线维持治疗的疗效与安全性，以期为临床实践提供关键依据。\n　　数据显示，接受氟唑帕利单药维持治疗的患者，全人群的位无进展生存期达29.9个月，相较于安慰剂组具有显著的统计学差异。在BRCA突变患者亚组中，氟唑帕利单药治疗将中位无进展生存期从安慰剂组的16.6个月大幅推升至47.8个月，疾病进展或死亡的风险显著降低。在HRD阳性人群，FZOCUS-1研究证实PARP抑制剂单药运用即可实现理想疗效，避免联合用药带来的副作用与经济负担。\n　　“FZOCUS-1研究全文在《CA》的成功发表，是中国临床肿瘤学研究的重要里程碑。” FZOCUS-1主要研究者，中国医学科学院肿瘤医院吴令英教授表示，“这项研究从设计、执行到数据分析，完全由中国团队独立完成，所有证据均来源于中国患者。它的价值不仅在于为中国患者提供了高级别的治疗选择，更在于为全球卵巢癌的治疗实践贡献了至关重要的‘中国数据’和‘中国智慧’。”\n　　恒瑞医药副总裁王泉人表示：“FZOCUS-1研究的成果，是恒瑞医药长期坚守‘科技为本，为人类创造健康生活’企业使命的生动体现。氟唑帕利从实验室发现到最终获得国际顶级学术认可，见证了中国原研药企依靠自主创新，解决全球临床难题的扎实历程。我们倍感自豪的是，这一‘中国智造’的创新成果，正在实现从‘服务中国患者’到‘贡献全球健康’的跨越。”王泉人进一步表示，“氟唑帕利已纳入医保目录，药物可及性大幅提升，我们正努力让更多的中国卵巢癌患者能以可负担的成本第一时间用上高质量的创新药。”\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：江钰涵","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591970396","isCrawlerRequest":true}